Thrivent Financial for Lutherans Increases Stake in Biogen Inc. $BIIB

Thrivent Financial for Lutherans raised its position in Biogen Inc. (NASDAQ:BIIB) by 351.2% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 82,091 shares of the biotechnology company’s stock after acquiring an additional 63,896 shares during the period. Thrivent Financial for Lutherans owned approximately 0.06% of Biogen worth $11,499,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Norges Bank acquired a new stake in Biogen in the second quarter valued at $284,358,000. Orion Porfolio Solutions LLC lifted its stake in shares of Biogen by 6,828.4% in the second quarter. Orion Porfolio Solutions LLC now owns 517,275 shares of the biotechnology company’s stock valued at $64,965,000 after purchasing an additional 509,809 shares during the period. Arrowstreet Capital Limited Partnership boosted its holdings in Biogen by 190.7% during the second quarter. Arrowstreet Capital Limited Partnership now owns 624,371 shares of the biotechnology company’s stock worth $78,415,000 after buying an additional 409,591 shares in the last quarter. AustralianSuper Pty Ltd grew its position in Biogen by 85.9% during the second quarter. AustralianSuper Pty Ltd now owns 739,416 shares of the biotechnology company’s stock worth $92,863,000 after buying an additional 341,719 shares during the period. Finally, Vanguard Group Inc. increased its holdings in Biogen by 1.5% in the second quarter. Vanguard Group Inc. now owns 17,290,651 shares of the biotechnology company’s stock valued at $2,171,533,000 after buying an additional 257,812 shares in the last quarter. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Biogen

In other Biogen news, insider Priya Singhal sold 748 shares of the business’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $179.30, for a total value of $134,116.40. Following the completion of the transaction, the insider directly owned 6,271 shares in the company, valued at approximately $1,124,390.30. The trade was a 10.66% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.18% of the company’s stock.

Biogen News Roundup

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Nature Medicine published pivotal DEVOTE results showing the high‑dose nusinersen regimen produced statistically significant motor and biomarker improvements versus lower dose / untreated comparators; safety was broadly consistent and the regimen is under FDA review with an April 3 PDUFA date — a clear potential revenue and label expansion catalyst for SPINRAZA. Nature Medicine Publishes DEVOTE Results
• Positive Sentiment: RBC Capital issued a buy/outperform view on BIIB, which supports upward price momentum by increasing institutional confidence and may attract more buyers ahead of earnings and the PDUFA decision. Biogen Receives a Buy from RBC Capital
• Neutral Sentiment: Market previews flag Q4 results and guidance as near‑term drivers — MS franchise pressures are a headwind but growth from newer assets (Leqembi, Skyclarys) could help offset declines; earnings delivery will likely drive short‑term volatility. Biogen Reports Q4: Everything You Need To Know Ahead Of Earnings
• Neutral Sentiment: Zacks preview notes new drug dynamics are key heading into Q4 — useful context but not an immediate directional trigger absent surprises in the print or guidance. New Drugs Take Center Stage as Biogen Heads Into Q4 Earnings
• Neutral Sentiment: Bernstein maintained a Hold (market‑perform) with a ~$191 target, signaling mixed near‑term fundamentals but acknowledging optional upside from emerging assets — this keeps analyst sentiment balanced. Biogen: Unexciting Near-Term Fundamentals but Optionality in Emerging Assets
• Negative Sentiment: An insider (Priya Singhal) disclosed a sale of 748 shares (~$134k) on Feb 2; small in size but sometimes viewed as a modest negative signal by some investors. Insider Form 4 — Priya Singhal Sale

Biogen Trading Up 4.9%

Shares of BIIB stock opened at $185.45 on Thursday. The company has a market capitalization of $27.21 billion, a price-to-earnings ratio of 16.91, a PEG ratio of 1.48 and a beta of 0.16. The company has a current ratio of 2.72, a quick ratio of 2.04 and a debt-to-equity ratio of 0.35. The firm has a 50-day moving average price of $176.48 and a 200 day moving average price of $155.92. Biogen Inc. has a twelve month low of $110.04 and a twelve month high of $190.20.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Weiss Ratings restated a “hold (c-)” rating on shares of Biogen in a report on Monday, December 29th. Jefferies Financial Group upped their target price on Biogen from $190.00 to $210.00 and gave the company a “buy” rating in a report on Friday, November 28th. Tudor Pickering set a $157.00 price target on Biogen in a research report on Monday, November 3rd. Guggenheim boosted their price objective on shares of Biogen from $165.00 to $185.00 in a research report on Friday, October 31st. Finally, Oppenheimer raised their target price on shares of Biogen from $205.00 to $225.00 and gave the company an “outperform” rating in a report on Friday, January 30th. Eleven research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $192.58.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.